Preparation and characterization of novel poly(ε-caprolactone)/biphasic calcium phosphate hybrid composite microspheres
Abstract
Desirably porous biodegradable hybrid composite microspheres were fabricated for use in bone graft and bone substitute applications. In this study, novel poly(ε-caprolactone)/biphasic calcium phosphate (70/30) composite microspheres (PCL/BCP MPs) were prepared using the emulsion solvent-evaporation method. Throughout this process, the ammonium bicarbonate (NH₄HCO₃) content was changed to obtain the desired porous structure. However, to maintain the spherical shape, the NH₄HCO₃ content should not be higher than 5%. In the optical images of the PCL/BCP MPs, almost all the microparticles had a spherical shape, and the average diameter was about 600 μm. The scanning electron microscopy and cross-sectional optical images showed that the pore density and pore diameter of PCL/BCP MPs increased with increasing initial NH₄HCO₃ concentrations. In the phase-composition analysis of the PCL/BCP MPs, which was characterized by X-ray diffraction and EDS, the two crystals BCP and PCL phases were shown to be miscible in PCL/BCP MPs. When the degradation of these microspheres was characterized, PCL/BCP MPs-0, PCL/BCP MPs-2, and PCL/BCP MPs-5 were found to display a sustained biodegradability, and the rate of degradation increased at higher initial NH₄HCO₃ concentrations. Proliferation of cells on three different sample types was assessed and compared, and based on these results, the PCL/BCP MPs-5 was chosen to study MG-63 osteoblast-cell adhesion, growth, and proliferation. Furthermore,…
How strong is the evidence?
Evidence Hub reads this as a experimental / empirical study, done in cell cultures (in vitro), not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.